Tauklarify (florquinitau F 18 injection) is a brain PET tracer that makes tau tangles visible in adults with memory problems being evaluated for Alzheimer's. Memory-clinic patients avoid overreading the headline by treating it as one piece of a specialist workup, not a standalone Alzheimer's diagnosis. Tau neurofibrillary tangles are twisted clumps of tau protein that build up inside brain cells. The scan binds selectively to that clumped tau, so bright spots on PET reflect one Alzheimer's hallmark alongside amyloid and clinical testing.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the scan actually shows
- Who the test is for
- Why positive and negative are not final
- What to ask at the memory clinic
What the scan actually shows
Tauklarify lights up aggregated tau, not memory loss itself. A trained reader looks for a pattern and spread consistent with Alzheimer's tau tangles. The result then joins history, thinking tests, and often amyloid testing.
Lantheus Holdings announced the approval on Aug. 14, 2026 as a radiodiagnostic for adults with cognitive impairment evaluated for Alzheimer's, described in the FDA approval notice. That narrow wording matters. It does not promise staging, prediction, or treatment selection by itself.
Who the test is for
The labeled group is adults who already have cognitive impairment and are seeing a clinician for possible Alzheimer's. Safety and effectiveness were not established for other tau-related brain disorders. So it is not a general brain check, dementia screen, or family-risk test.
A person with steady memory complaints, abnormal office testing, and an unclear cause fits the conversation. A person with normal thinking, Parkinson's signs, or suspected frontotemporal disease generally does not. Your neurologist or memory specialist decides whether tau PET would change the plan.
Why positive and negative are not final
Two blinded read studies in 617 participants found positive agreement of 68%-88% and negative agreement of 93%-99%, with strong reader consistency, as reported by Pharmacy Times in its approval summary. Agreement was strongest at the clear ends of the spectrum. Early or borderline disease is harder to call.
The label warns that a negative scan does not rule out tau pathology. A positive scan alone does not prove Alzheimer's disease under the microscope. Pharmacy Times also noted performance was set mainly in amyloid-negative healthy people versus amyloid-positive impaired patients, so accuracy may drop earlier in the disease course.
What to ask at the memory clinic
Use tau PET only as an add-on to expert evaluation under updated amyloid and tau PET appropriate-use guidance, a point emphasized by the Alzheimer's Association in its criteria update. Ask how the result would alter diagnosis, care, or trial eligibility.
Ask what other tests are still needed if the scan and symptoms disagree. Write down the reader's exact phrase: negative, positive, uncertain, or non-Alzheimer's pattern. Then ask what follow-up closes the gap.
- Bring a full drug, smoking, breastfeeding, and prior scan history to the visit
- Ask about radiation safety, hydration and frequent voiding after injection
- Confirm the plan for 7 days without smoking or CYP1A2 inducers, when advised
- Pause breastfeeding for 4 hours after the dose, if applicable
- Report headache or nausea, seen in 0.7% and 0.2% of 1,734 study participants
You Might Also Like
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: How Memory Clinic Patients Can Avoid Overreading the Headline
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: How Memory Clinic Patients Can Avoid Overreading the Headline
- Tauklarify Tau PET vs Alzheimer’s Blood Tests in 2026: A Source-Checked Briefing for Memory Clinic Patients
